Assignee
EMPROS PHARMA AB
SE·2 granted patents·3 pending applications·0 citations·filing 2015–2024
Top patents by PatentIndex Score
5 records- 0164US2024342096A1Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disordersEMPROS PHARMA AB·Filed 2024·Application pending·0 cites
- 0252US11975105B2Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disordersEMPROS PHARMA AB·Filed 2020·Granted May 7, 2024·0 cites·15 claims
- 0342US2025127752A1Reduced rebound effects in subjects treated for overweight or obesityEMPROS PHARMA AB·Filed 2022·Application pending·0 cites
- 0442US2024226024A1Synergistic effects on weight loss, improved quality of life and reduced gastro-intestinal side effects with a composition of orlistat and acarboseEMPROS PHARMA AB·Filed 2022·Application pending·0 cites
- 0537US10561617B2Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disordersEMPROS PHARMA AB·Filed 2015·Granted Feb 18, 2020·0 cites·27 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →